

# rakon



## Rakon Limited Interim Report September 2018



## Table of Contents

---

|                                                                  |    |
|------------------------------------------------------------------|----|
| Unaudited Consolidated Interim Statement of Comprehensive Income | 2  |
| Unaudited Consolidated Interim Statement of Changes in Equity    | 3  |
| Unaudited Consolidated Interim Balance Sheet                     | 4  |
| Unaudited Consolidated Interim Statement of Cash Flows           | 5  |
| Notes to the Unaudited Consolidated Interim Financial Statements | 7  |
| Directory                                                        | 16 |

# Unaudited Consolidated Interim Statement of Comprehensive Income

For the period ended 30 September 2018

|                                                                                                                   |       | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|-------------------------------------------------------------------------------------------------------------------|-------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
|                                                                                                                   | Note  |                                                                 |                                                                 |                                                     |
| <b>Continuing operations</b>                                                                                      |       |                                                                 |                                                                 |                                                     |
| Revenue                                                                                                           | B1 d) | 53,309                                                          | 48,278                                                          | 101,127                                             |
| Cost of sales                                                                                                     |       | (28,715)                                                        | (28,137)                                                        | (57,828)                                            |
| <b>Gross profit</b>                                                                                               |       | <b>24,594</b>                                                   | <b>20,141</b>                                                   | <b>43,299</b>                                       |
| Other operating income                                                                                            | B3    | 1                                                               | 688                                                             | 2,421                                               |
| Other gains – net                                                                                                 |       | 645                                                             | 492                                                             | 4,624                                               |
| Re-measurement on change in treatment – Thinextra shares                                                          | B5 c) | 7,172                                                           | -                                                               | -                                                   |
| Net loss from business combination                                                                                | B4 b) | (69)                                                            | -                                                               | -                                                   |
| Operating expenses                                                                                                | B2    | (23,492)                                                        | (19,490)                                                        | (41,626)                                            |
| Impairment                                                                                                        |       | -                                                               | -                                                               | (120)                                               |
| <b>Operating profit</b>                                                                                           |       | <b>8,851</b>                                                    | <b>1,831</b>                                                    | <b>8,598</b>                                        |
| Finance income                                                                                                    |       | 9                                                               | -                                                               | 3                                                   |
| Finance costs                                                                                                     |       | (186)                                                           | (227)                                                           | (504)                                               |
| Share of net profits/(losses) of associates and joint venture                                                     | B5 b) | 570                                                             | (543)                                                           | (1,915)                                             |
| Net dilution gain on Thinextra shares                                                                             |       | -                                                               | -                                                               | 4,815                                               |
| <b>Profit before income tax</b>                                                                                   |       | <b>9,244</b>                                                    | <b>1,061</b>                                                    | <b>10,997</b>                                       |
| Income tax expense                                                                                                |       | (45)                                                            | (153)                                                           | (998)                                               |
| <b>Net profit for the period</b>                                                                                  |       | <b>9,199</b>                                                    | <b>908</b>                                                      | <b>9,999</b>                                        |
| <b>Other comprehensive income</b>                                                                                 |       |                                                                 |                                                                 |                                                     |
| Items that may be reclassified subsequently to profit or loss                                                     |       |                                                                 |                                                                 |                                                     |
| Decrease in fair value cash flow hedges                                                                           |       | (3,454)                                                         | (313)                                                           | (372)                                               |
| Cost of hedging                                                                                                   |       | 154                                                             | -                                                               | -                                                   |
| Increase in fair value currency translation differences                                                           |       | 2,125                                                           | 1,467                                                           | 2,766                                               |
| Income tax credit relating to components of other comprehensive income                                            |       | 967                                                             | 88                                                              | 104                                                 |
| <b>Other comprehensive (losses)/income for the period, net of tax</b>                                             |       | <b>(208)</b>                                                    | <b>1,242</b>                                                    | <b>2,498</b>                                        |
| <b>Total comprehensive income for the period</b>                                                                  |       | <b>8,991</b>                                                    | <b>2,150</b>                                                    | <b>12,497</b>                                       |
| <b>Profit attributable to equity holders of the Company</b>                                                       |       | <b>9,199</b>                                                    | <b>908</b>                                                      | <b>9,999</b>                                        |
| <b>Total comprehensive profit attributable to equity holders of the Company</b>                                   |       | <b>8,991</b>                                                    | <b>2,150</b>                                                    | <b>12,497</b>                                       |
| <b>Earnings per share for profit attributable to the equity holders of the Company from continuing operations</b> |       |                                                                 |                                                                 |                                                     |
|                                                                                                                   |       | <b>Cents</b>                                                    | <b>Cents</b>                                                    | <b>Cents</b>                                        |
| Basic earnings per share                                                                                          |       | 4.1                                                             | 0.4                                                             | 4.4                                                 |
| Diluted earnings per share                                                                                        |       | 4.0                                                             | 0.4                                                             | 4.3                                                 |

The accompanying notes form an integral part of these financial statements.

# Unaudited Consolidated Interim Statement of Changes in Equity

## For the period ended 30 September 2018

|                                                                | Share capital<br>\$000s | Retained<br>earnings<br>\$000s | Other reserves<br>\$000s | Total equity<br>\$000s |
|----------------------------------------------------------------|-------------------------|--------------------------------|--------------------------|------------------------|
| <b>Balance at 31 March 2017</b>                                | <b>181,035</b>          | <b>(83,218)</b>                | <b>(23,260)</b>          | <b>74,557</b>          |
| Net profit after tax for the half year ended 30 September 2017 | -                       | 908                            | -                        | 908                    |
| Contribution of equity, transaction cost                       | (11)                    | -                              | -                        | (11)                   |
| Currency translation differences                               | -                       | -                              | 1,467                    | 1,467                  |
| Cash flow hedges, net of tax                                   | -                       | -                              | (225)                    | (225)                  |
| <b>Total comprehensive loss for the half year</b>              | <b>(11)</b>             | <b>908</b>                     | <b>1,242</b>             | <b>2,139</b>           |
| Employee share schemes                                         |                         |                                |                          |                        |
| Value of employee services                                     | -                       | -                              | 8                        | 8                      |
| <b>Balance at 30 September 2017</b>                            | <b>181,024</b>          | <b>(82,310)</b>                | <b>(22,010)</b>          | <b>76,704</b>          |
| Net profit after tax for the half year ended 31 March 2018     | -                       | 9,091                          | -                        | 9,091                  |
| Currency translation differences                               | -                       | -                              | 1,299                    | 1,299                  |
| Cash flow hedges, net of tax                                   | -                       | -                              | (43)                     | (43)                   |
| <b>Total comprehensive income for the half year</b>            | <b>-</b>                | <b>9,091</b>                   | <b>1,256</b>             | <b>10,347</b>          |
| <b>Balance at 31 March 2018</b>                                | <b>181,024</b>          | <b>(73,219)</b>                | <b>(20,754)</b>          | <b>87,051</b>          |
| Net profit after tax for the half year ended 30 September 2018 | -                       | 9,199                          | -                        | 9,199                  |
| Currency translation differences                               | -                       | -                              | 2,125                    | 2,125                  |
| Cash flow hedges, net of tax                                   | -                       | -                              | (2,333)                  | (2,333)                |
| <b>Total comprehensive income for the half year</b>            | <b>-</b>                | <b>9,199</b>                   | <b>(208)</b>             | <b>8,991</b>           |
| <b>Balance at 30 September 2018</b>                            | <b>181,024</b>          | <b>(64,020)</b>                | <b>(20,962)</b>          | <b>96,042</b>          |

The accompanying notes form an integral part of these financial statements.

# Unaudited Consolidated Interim Balance Sheet

As at 30 September 2018

|                                                                  |       | Unaudited six<br>months ended<br>30 September<br>2018 | Unaudited six<br>months ended<br>30 September<br>2017 | Audited year<br>ended<br>31 March<br>2018 |
|------------------------------------------------------------------|-------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------|
|                                                                  | Note  | \$000s                                                | \$000s                                                | \$000s                                    |
| <b>Assets</b>                                                    |       |                                                       |                                                       |                                           |
| <b>Current assets</b>                                            |       |                                                       |                                                       |                                           |
| Cash and cash equivalents                                        |       | 2,629                                                 | 3,566                                                 | 10,364                                    |
| Trade and other receivables                                      |       | 34,973                                                | 22,824                                                | 28,395                                    |
| Financial asset at fair value through profit and loss            |       | 11                                                    | 65                                                    | 211                                       |
| Derivative financial instruments                                 |       | 69                                                    | 676                                                   | 1,078                                     |
| Inventories                                                      |       | 37,444                                                | 26,281                                                | 24,171                                    |
| Current income tax asset                                         |       | 820                                                   | 10                                                    | 146                                       |
| Assets classified as held for sale                               |       | -                                                     | 2,090                                                 | -                                         |
| <b>Total current assets</b>                                      |       | <b>75,946</b>                                         | <b>55,512</b>                                         | <b>64,365</b>                             |
| <b>Non-current assets</b>                                        |       |                                                       |                                                       |                                           |
| Trade and other receivables                                      |       | 2,959                                                 | 2,166                                                 | 2,716                                     |
| Property, plant and equipment                                    |       | 17,243                                                | 11,113                                                | 13,481                                    |
| Intangible assets                                                |       | 10,276                                                | 10,780                                                | 9,115                                     |
| Derivative financial instruments                                 |       | 278                                                   | 673                                                   | 334                                       |
| Financial asset at fair value through other comprehensive income | B5 c) | 12,176                                                | -                                                     | -                                         |
| Investment in associates                                         | B5 b) | 9,954                                                 | 11,602                                                | 14,640                                    |
| Interest in joint venture                                        | B5 b) | -                                                     | 3,451                                                 | 2,876                                     |
| Deferred tax asset                                               |       | 8,209                                                 | 6,560                                                 | 5,906                                     |
| <b>Total non-current assets</b>                                  |       | <b>61,095</b>                                         | <b>46,345</b>                                         | <b>49,068</b>                             |
| <b>Total assets</b>                                              |       | <b>137,041</b>                                        | <b>101,857</b>                                        | <b>113,433</b>                            |
| <b>Liabilities</b>                                               |       |                                                       |                                                       |                                           |
| <b>Current liabilities</b>                                       |       |                                                       |                                                       |                                           |
| Bank overdraft                                                   |       | 6,201                                                 | 1,362                                                 | 2,824                                     |
| Borrowings                                                       |       | 294                                                   | 2,526                                                 | 98                                        |
| Trade and other payables                                         |       | 26,169                                                | 15,652                                                | 19,107                                    |
| Derivative financial instruments                                 |       | 1,550                                                 | 168                                                   | 235                                       |
| Provisions                                                       |       | 354                                                   | 464                                                   | 961                                       |
| Deferred consideration                                           | B4 a) | 1,832                                                 | -                                                     | -                                         |
| Deferred revenue                                                 |       | 101                                                   | 1,847                                                 | 101                                       |
| <b>Total current liabilities</b>                                 |       | <b>36,501</b>                                         | <b>22,019</b>                                         | <b>23,326</b>                             |
| <b>Non-current liabilities</b>                                   |       |                                                       |                                                       |                                           |
| Derivative financial instruments                                 |       | 1,154                                                 | 159                                                   | 78                                        |
| Borrowings                                                       |       | -                                                     | 19                                                    | -                                         |
| Provisions                                                       |       | 3,100                                                 | 2,922                                                 | 2,734                                     |
| Deferred tax liabilities                                         |       | 244                                                   | 34                                                    | 244                                       |
| <b>Total non-current liabilities</b>                             |       | <b>4,498</b>                                          | <b>3,134</b>                                          | <b>3,056</b>                              |
| <b>Total liabilities</b>                                         |       | <b>40,999</b>                                         | <b>25,153</b>                                         | <b>26,382</b>                             |
| <b>Net assets</b>                                                |       | <b>96,042</b>                                         | <b>76,704</b>                                         | <b>87,051</b>                             |
| <b>Equity</b>                                                    |       |                                                       |                                                       |                                           |
| Share capital                                                    |       | 181,024                                               | 181,024                                               | 181,024                                   |
| Other reserves                                                   |       | (20,962)                                              | (22,010)                                              | (20,754)                                  |
| Accumulated losses                                               |       | (64,020)                                              | (82,310)                                              | (73,219)                                  |
| <b>Total equity</b>                                              |       | <b>96,042</b>                                         | <b>76,704</b>                                         | <b>87,051</b>                             |

The accompanying notes form an integral part of these financial statements.

# Unaudited Consolidated Interim Statement of Cash Flows

For the period ended 30 September 2018

|                                                               | Unaudited six<br>months ended<br>30 September<br>2018<br>Note | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|---------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| <b>Operating activities</b>                                   |                                                               |                                                                 |                                                     |
| <b>Cash provided from</b>                                     |                                                               |                                                                 |                                                     |
| Receipts from customers                                       | 54,754                                                        | 52,124                                                          | 101,691                                             |
| Income tax refund                                             | 29                                                            | -                                                               | -                                                   |
| R&D grants received                                           | 305                                                           | 1,405                                                           | 1,726                                               |
| Other income received                                         | 9                                                             | -                                                               | 3                                                   |
|                                                               | <b>55,097</b>                                                 | <b>53,529</b>                                                   | <b>103,420</b>                                      |
| <b>Cash was applied to</b>                                    |                                                               |                                                                 |                                                     |
| Payment to suppliers and others                               | (34,598)                                                      | (29,622)                                                        | (57,998)                                            |
| Payment to employees                                          | (23,680)                                                      | (18,668)                                                        | (36,735)                                            |
| Interest paid                                                 | (140)                                                         | (248)                                                           | (536)                                               |
| Income tax paid                                               | (107)                                                         | (62)                                                            | (247)                                               |
|                                                               | <b>(58,525)</b>                                               | <b>(48,600)</b>                                                 | <b>(95,516)</b>                                     |
| <b>Net cash flow from operating activities</b>                | <b>(3,428)</b>                                                | <b>4,929</b>                                                    | <b>7,904</b>                                        |
| <b>Investing activities</b>                                   |                                                               |                                                                 |                                                     |
| <b>Cash was provided from</b>                                 |                                                               |                                                                 |                                                     |
| Net proceeds from sale of Thinextra shares                    | -                                                             | -                                                               | 3,178                                               |
| Sale of property, plant and equipment                         | 16                                                            | -                                                               | 4,754                                               |
|                                                               | <b>16</b>                                                     | <b>-</b>                                                        | <b>7,932</b>                                        |
| <b>Cash was applied to</b>                                    |                                                               |                                                                 |                                                     |
| Purchase of property, plant and equipment                     | (2,115)                                                       | (255)                                                           | (3,236)                                             |
| Purchase of intangibles                                       | (223)                                                         | (688)                                                           | (840)                                               |
| Investment in shares and associates                           | (5,848)                                                       | -                                                               | -                                                   |
|                                                               | <b>(8,186)</b>                                                | <b>(943)</b>                                                    | <b>(4,076)</b>                                      |
| <b>Net cash flow from investing activities</b>                | <b>(8,170)</b>                                                | <b>(943)</b>                                                    | <b>3,856</b>                                        |
| <b>Financing activities</b>                                   |                                                               |                                                                 |                                                     |
| <b>Cash was applied to</b>                                    |                                                               |                                                                 |                                                     |
| Share issuance cost                                           | -                                                             | (11)                                                            | (11)                                                |
| Repayment of principal on borrowings                          | -                                                             | (2,016)                                                         | (4,500)                                             |
| Finance lease payments                                        | (13)                                                          | -                                                               | (31)                                                |
|                                                               | <b>(13)</b>                                                   | <b>(2,027)</b>                                                  | <b>(4,542)</b>                                      |
| <b>Net cash flow from financing activities</b>                | <b>(13)</b>                                                   | <b>(2,027)</b>                                                  | <b>(4,542)</b>                                      |
| <b>Net (decrease)/increase in cash and cash equivalents</b>   | <b>(11,611)</b>                                               | <b>1,959</b>                                                    | <b>7,218</b>                                        |
| Effects of exchange rate changes on cash and cash equivalents | 499                                                           | 169                                                             | 246                                                 |
| Cash and cash equivalents at the beginning of the year        | 7,540                                                         | 76                                                              | 76                                                  |
| <b>Cash and cash equivalents at the end of the period</b>     | <b>(3,572)</b>                                                | <b>2,204</b>                                                    | <b>7,540</b>                                        |
| <b>Composition of cash and cash equivalents</b>               |                                                               |                                                                 |                                                     |
| Cash and cash equivalents                                     | 2,629                                                         | 3,566                                                           | 10,364                                              |
| Bank overdraft                                                | (6,201)                                                       | (1,362)                                                         | (2,824)                                             |
| <b>Total cash and cash equivalents</b>                        | <b>(3,572)</b>                                                | <b>2,204</b>                                                    | <b>7,540</b>                                        |

The accompanying notes form an integral part of these financial statements.

# Unaudited Consolidated Interim Statement of Cash Flows

## For the period ended 30 September 2018

|                                                                                 | Note  | Unaudited six<br>months ended<br>30 September<br>2018 | Unaudited six<br>months ended<br>30 September<br>2017 | Audited year<br>ended<br>31 March<br>2018 |
|---------------------------------------------------------------------------------|-------|-------------------------------------------------------|-------------------------------------------------------|-------------------------------------------|
| <b>Reconciliation of net profit to net cash flows from operating activities</b> |       |                                                       |                                                       |                                           |
| <b>Reported net profit after tax</b>                                            |       | <b>9,199</b>                                          | <b>908</b>                                            | <b>9,999</b>                              |
| <b>Following adjustments</b>                                                    |       |                                                       |                                                       |                                           |
| Depreciation expense                                                            |       | 1,716                                                 | 1,336                                                 | 2,504                                     |
| Amortisation expense                                                            |       | 1,065                                                 | 971                                                   | 1,838                                     |
| Impairment                                                                      |       | -                                                     | -                                                     | 120                                       |
| Increase in estimated doubtful debts                                            |       | -                                                     | 7                                                     | 7                                         |
| Provision for restructure                                                       |       | -                                                     | -                                                     | 159                                       |
| Employee share based expense                                                    |       | -                                                     | 8                                                     | 8                                         |
| Movement in foreign currency                                                    |       | (32)                                                  | (16)                                                  | (590)                                     |
| Monetised cash flow hedge, net of tax                                           |       | -                                                     | (941)                                                 | (1,096)                                   |
| Deferred revenue –Siward technology license agreement                           |       | -                                                     | (687)                                                 | (2,351)                                   |
| Share of net (profits)/losses of associates and joint venture                   | B5 b) | (570)                                                 | 543                                                   | 1,915                                     |
| Deferred tax                                                                    |       | -                                                     | -                                                     | 382                                       |
| (Gain)/loss on disposal of property, plant and equipment                        |       | (16)                                                  | 12                                                    | (2,155)                                   |
| Thinextra shares – fair value adjustment                                        | B5 c) | (7,172)                                               | -                                                     | (1,852)                                   |
| Net dilution gain on Thinextra shares                                           |       | -                                                     | -                                                     | (4,815)                                   |
| Net loss from business combination                                              | B4 b) | 69                                                    | -                                                     | -                                         |
| <b>Total items cash flow adjusted for</b>                                       |       | <b>(4,940)</b>                                        | <b>1,233</b>                                          | <b>(5,926)</b>                            |
| <b>Impact of changes in working capital items</b>                               |       |                                                       |                                                       |                                           |
| Trade and other receivables                                                     |       | (2,268)                                               | 5,424                                                 | (146)                                     |
| Provision for restructure                                                       |       | (252)                                                 | (420)                                                 | (645)                                     |
| Inventories                                                                     |       | (7,404)                                               | (1,995)                                               | 115                                       |
| Trade and other payables                                                        |       | 2,278                                                 | (307)                                                 | 4,557                                     |
| Tax provisions                                                                  |       | (41)                                                  | 86                                                    | (50)                                      |
| <b>Total impact of changes in working capital items</b>                         |       | <b>(7,687)</b>                                        | <b>2,788</b>                                          | <b>3,831</b>                              |
| <b>Net cash flow from operating activities</b>                                  |       | <b>(3,428)</b>                                        | <b>4,929</b>                                          | <b>7,904</b>                              |

The accompanying notes form an integral part of these financial statements.

# Notes to the Unaudited Consolidated Interim Financial Statements

## A. General information

Rakon Limited ('the Company') and its subsidiaries ('the Group') design and manufacture frequency control solutions for a wide range of applications. Rakon has leading market positions in the supply of crystal oscillators to the Telecommunications, Global Positioning and Space & Defence markets. The Company is a limited liability company incorporated and domiciled in New Zealand. It is registered under the Companies Act 1993 with its registered office at 8 Sylvia Park Road, Mt Wellington, Auckland.

The financial statements of the Group have been presented in New Zealand dollars unless otherwise indicated and have been approved for issue by Rakon's Board of Directors ('the Board') on 15 November 2018.

## B. Calculation of key numbers

### B1. Segment information

The chief operating decision maker assesses the performance of the operating segments based on a non-GAAP measure of 'Underlying EBITDA' defined as:

'Earnings before interest, tax, depreciation, amortisation, impairment, employee share schemes, non-controlling interests, adjustments for associates and joint venture's share of interest, tax & depreciation, loss on disposal of assets and other cash and non-cash items (Underlying EBITDA)', refer note B1 c).

Underlying EBITDA is a non-GAAP measure that has not been presented in accordance with GAAP. The Directors present Underlying EBITDA as a useful non-GAAP measure to investors, in order to understand the underlying operating performance of the Group and each operating segment, before the adjustment of specific cash and non-cash items and before cash impacts relating to the capital structure and tax position. Underlying EBITDA is considered by the Directors to be the closest measure of how each operating segment within the Group is performing. Management uses the non-GAAP measure of Underlying EBITDA internally, to assess the underlying operating performance of the Group and each operating segment.

Underlying EBITDA as non-GAAP financial information has been extracted from the financial statements for the period. Except for Underlying EBITDA, other information provided to the chief operating decision maker is measured in a manner consistent with GAAP. The Directors provide a reconciliation of Underlying EBITDA to net profit for the period, refer note B1 c).

#### B1 a) Accounting policy

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Managing Director, Sales and Marketing Director and Chief Financial Officer.

#### B1 b) Segment results

#### Unaudited six months ended 30 September 2018

|                                                         | NZ     | UK     | France  | India <sup>7</sup> | China–<br>T'maker <sup>1</sup> | India–<br>Centum<br>Rakon <sup>2</sup> | Australia–<br>Thinextra <sup>6</sup> | Other <sup>3</sup> | Total   |
|---------------------------------------------------------|--------|--------|---------|--------------------|--------------------------------|----------------------------------------|--------------------------------------|--------------------|---------|
|                                                         | \$000s | \$000s | \$000s  | \$000s             | \$000s                         | \$000s                                 | \$000s                               | \$000s             | \$000s  |
| Sales to external customers                             | 32,726 | -      | 18,603  | 1,980              | -                              | -                                      | -                                    | -                  | 53,309  |
| Inter-segment sales                                     | 174    | -      | 104     | 8,288              | -                              | -                                      | -                                    | -                  | 8,566   |
| Segment revenue                                         | 32,900 | -      | 18,707  | 10,268             | -                              | -                                      | -                                    | -                  | 61,875  |
| Underlying EBITDA                                       | 6,186  | 848    | (3,457) | 1,294              | 1,355                          | 124                                    | (289)                                | (182)              | 5,879   |
| Depreciation and amortisation                           | 1,138  | 258    | 900     | 484                | -                              | -                                      | -                                    | 1                  | 2,781   |
| Income tax (expense)/credit                             | -      | 43     | 16      | -                  | -                              | -                                      | -                                    | (104)              | (45)    |
| Total assets <sup>4</sup>                               | 56,323 | 3,373  | 32,591  | 21,177             | 9,954                          | -                                      | -                                    | 13,623             | 137,041 |
| Investment in associates                                | -      | -      | -       | -                  | 9,954                          | -                                      | -                                    | -                  | 9,954   |
| Additions of property, plant, equipment and intangibles | 1,130  | 271    | 547     | 109                | -                              | -                                      | -                                    | -                  | 2,057   |
| Total liabilities <sup>5</sup>                          | 19,631 | 471    | 12,743  | 8,019              | -                              | -                                      | -                                    | 135                | 40,999  |

**Unaudited six months ended 30 September 2017**

|                                                         | NZ     | UK     | France  | India <sup>7</sup> | China–<br>T'maker <sup>1</sup> | India–<br>Centum<br>Rakon <sup>2</sup> | Australia–<br>Thinextra <sup>6</sup> | Other <sup>3</sup> | Total   |
|---------------------------------------------------------|--------|--------|---------|--------------------|--------------------------------|----------------------------------------|--------------------------------------|--------------------|---------|
|                                                         | \$000s | \$000s | \$000s  | \$000s             | \$000s                         | \$000s                                 | \$000s                               | \$000s             | \$000s  |
| Sales to external customers                             | 32,072 | -      | 16,206  | -                  | -                              | -                                      | -                                    | -                  | 48,278  |
| Inter-segment sales                                     | 90     | -      | -       | -                  | -                              | -                                      | -                                    | 19                 | 109     |
| Segment revenue                                         | 32,162 | -      | 16,206  | -                  | -                              | -                                      | -                                    | 19                 | 48,387  |
| Underlying EBITDA                                       | 3,953  | 815    | (1,327) | -                  | 1,389                          | 371                                    | (1,272)                              | (129)              | 3,800   |
| Depreciation and amortisation                           | 1,297  | 251    | 675     | -                  | -                              | -                                      | -                                    | 84                 | 2,307   |
| Income tax (expense)/credit                             | -      | (91)   | 14      | -                  | -                              | -                                      | -                                    | (76)               | (153)   |
| Total assets <sup>4</sup>                               | 48,275 | 3,164  | 29,828  | -                  | 8,798                          | 3,451                                  | 5,608                                | 2,733              | 101,857 |
| Investment in associates                                | -      | -      | -       | -                  | 8,798                          | -                                      | -                                    | 2,804              | 11,602  |
| Investment in joint venture                             | -      | -      | -       | -                  | -                              | 3,451                                  | -                                    | -                  | 3,451   |
| Additions of property, plant, equipment and intangibles | 690    | 164    | 198     | -                  | -                              | -                                      | -                                    | -                  | 1,052   |
| Total liabilities <sup>5</sup>                          | 13,004 | 482    | 11,197  | -                  | -                              | -                                      | -                                    | 470                | 25,153  |

**Audited year ended 31 March 2018**

|                                                         | NZ     | UK     | France | India <sup>7</sup> | China–<br>T'maker <sup>1</sup> | India–<br>Centum<br>Rakon <sup>2</sup> | Australia–<br>Thinextra <sup>6</sup> | Other <sup>3</sup> | Total   |
|---------------------------------------------------------|--------|--------|--------|--------------------|--------------------------------|----------------------------------------|--------------------------------------|--------------------|---------|
|                                                         | \$000s | \$000s | \$000s | \$000s             | \$000s                         | \$000s                                 | \$000s                               | \$000s             | \$000s  |
| Sales to external customers                             | 63,812 | -      | 37,315 | -                  | -                              | -                                      | -                                    | -                  | 101,127 |
| Inter-segment sales                                     | 163    | -      | 5      | -                  | -                              | -                                      | -                                    | 33                 | 201     |
| Segment revenue                                         | 63,975 | -      | 37,320 | -                  | -                              | -                                      | -                                    | 33                 | 101,328 |
| Underlying EBITDA                                       | 7,611  | 1,591  | 1,334  | -                  | 2,115                          | (9)                                    | (430)                                | (118)              | 12,094  |
| Depreciation and amortisation                           | 2,517  | 508    | 1,408  | -                  | -                              | -                                      | -                                    | (91)               | 4,342   |
| Impairment                                              | 120    | -      | -      | -                  | -                              | -                                      | -                                    | -                  | 120     |
| Income tax (expense)/credit                             | (623)  | (129)  | 29     | -                  | -                              | -                                      | -                                    | (275)              | (998)   |
| Total assets <sup>4</sup>                               | 51,819 | 3,255  | 37,326 | -                  | 9,350                          | 2,876                                  | 5,290                                | 3,517              | 113,433 |
| Investment in associates                                | -      | -      | -      | -                  | 9,350                          | -                                      | 5,290                                | -                  | 14,640  |
| Investment in joint venture                             | -      | -      | -      | -                  | -                              | 2,876                                  | -                                    | -                  | 2,876   |
| Additions of property, plant, equipment and intangibles | 2,463  | 441    | 1,255  | -                  | -                              | -                                      | -                                    | 4                  | 4,163   |
| Total liabilities <sup>5</sup>                          | 11,987 | 462    | 13,459 | -                  | -                              | -                                      | -                                    | 474                | 26,382  |

<sup>1</sup> Includes Rakon Limited's 40% share of investment in Chengdu Timemaker Crystal Technology Co. Limited and Shenzhen Taixiang Wafer Co. Limited, refer note B5.

<sup>2</sup> Included Rakon Limited's 49% share of investment in Centum Rakon India Private Limited, refer note B5.

<sup>3</sup> Includes investments in subsidiaries, Rakon Financial Services Limited, Rakon UK Holdings Limited, Rakon Investment HK Limited, and Rakon HK Limited, and the reclassified equity investment in Thinextra Pty Limited.

<sup>4</sup> The measure of assets has been disclosed for each reportable segment as it is regularly provided to the chief operating decision maker and excludes intercompany balances eliminated on consolidation.

<sup>5</sup> The measure of liabilities has been disclosed for each reportable segment as it is regularly provided to the chief operating decision maker and excludes intercompany balances eliminated on consolidation.

<sup>6</sup> On 1 June 2018, share equity investment in Thinextra Pty Limited was reclassified as financial instrument fair value through other comprehensive income, now reported under Other, refer to note B5 c).

<sup>7</sup> On 2 May 2018, the Group acquired the remaining 51% of the issued shares it did not own in Centum Rakon India Private Limited ('CRI'), a previously held joint venture, refer to note B4 b).

**B1 c) Reconciliation of Underlying EBITDA to net profit for the period**

|                                                                                     | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|-------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| <b>Continuing operations</b>                                                        |                                                                 |                                                                 |                                                     |
| Underlying EBITDA                                                                   | 5,879                                                           | 3,800                                                           | 12,094                                              |
| Depreciation and amortisation                                                       | (2,781)                                                         | (2,307)                                                         | (4,342)                                             |
| One off cash gains realised on derivatives closed out                               | -                                                               | 941                                                             | 1,096                                               |
| Employee share schemes                                                              | -                                                               | (8)                                                             | (8)                                                 |
| Finance costs – net                                                                 | (177)                                                           | (227)                                                           | (501)                                               |
| Adjustment for associates and joint venture share of interest, tax and depreciation | (648)                                                           | (1,032)                                                         | (1,751)                                             |
| Net dilution gain on Thinxtra shares                                                | -                                                               | -                                                               | 4,815                                               |
| Impairment                                                                          | -                                                               | -                                                               | (120)                                               |
| Loss on asset sales/disposal                                                        | (20)                                                            | (12)                                                            | (25)                                                |
| Re-measurement on change in treatment – Thinxtra shares                             | 7,172                                                           | -                                                               | -                                                   |
| Other non-cash items                                                                | (181)                                                           | (94)                                                            | (261)                                               |
| <b>Profit before income tax</b>                                                     | <b>9,244</b>                                                    | <b>1,061</b>                                                    | <b>10,997</b>                                       |
| Income tax expense                                                                  | (45)                                                            | (153)                                                           | (998)                                               |
| <b>Net profit for the period</b>                                                    | <b>9,199</b>                                                    | <b>908</b>                                                      | <b>9,999</b>                                        |

**B1 d) Breakdown of revenue by goods and services**

|                       | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|-----------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| Sales of goods        | 52,783                                                          | 47,868                                                          | 99,916                                              |
| Revenue from services | 526                                                             | 410                                                             | 1,211                                               |
| <b>Total revenue</b>  | <b>53,309</b>                                                   | <b>48,278</b>                                                   | <b>101,127</b>                                      |

**B1 e) Breakdown of revenue by market segment**

|                                        | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|----------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| Telecommunications                     | 24,289                                                          | 21,384                                                          | 40,457                                              |
| Global Positioning                     | 11,424                                                          | 13,065                                                          | 25,999                                              |
| Space and Defence                      | 14,204                                                          | 10,677                                                          | 27,984                                              |
| Other                                  | 3,392                                                           | 3,152                                                           | 6,687                                               |
| <b>Total revenue by market segment</b> | <b>53,309</b>                                                   | <b>48,278</b>                                                   | <b>101,127</b>                                      |

## B1 f) Breakdown of revenue by region

The Group's trading revenue is derived in the following regions. Revenue is allocated based on the country in which the customer is located.

|                                | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|--------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| Asia                           | 25,259                                                          | 20,390                                                          | 41,330                                              |
| North America                  | 12,704                                                          | 10,809                                                          | 23,940                                              |
| Europe                         | 14,030                                                          | 15,989                                                          | 33,069                                              |
| Others                         | 1,316                                                           | 1,090                                                           | 2,788                                               |
| <b>Total revenue by region</b> | <b>53,309</b>                                                   | <b>48,278</b>                                                   | <b>101,127</b>                                      |

## B2. Operating expenses

|                                      | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|--------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| <b>Operating expense by function</b> |                                                                 |                                                                 |                                                     |
| Selling and marketing costs          | 4,945                                                           | 4,439                                                           | 9,905                                               |
| Research and development             | 5,556                                                           | 5,292                                                           | 9,712                                               |
| General and administration           | 12,991                                                          | 9,759                                                           | 22,009                                              |
| <b>Total operating expenses</b>      | <b>23,492</b>                                                   | <b>19,490</b>                                                   | <b>41,626</b>                                       |

## B3. Other operating income

|                                                      | Unaudited six<br>months ended<br>30 September<br>2018<br>\$000s | Unaudited six<br>months ended<br>30 September<br>2017<br>\$000s | Audited year<br>ended<br>31 March<br>2018<br>\$000s |
|------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------|
| Dividend income                                      | -                                                               | 1                                                               | 1                                                   |
| Other income                                         | 1                                                               | -                                                               | 69                                                  |
| Income from technology license agreement with Siward | -                                                               | 687                                                             | 2,351                                               |
| <b>Total other operating income</b>                  | <b>1</b>                                                        | <b>688</b>                                                      | <b>2,421</b>                                        |

## B4. Business combination – acquisition of Centum Rakon India Private Limited

### B4 a) Current period

On 2 May 2018, the Group acquired the remaining 51% of the issued shares it did not own in Centum Rakon India Private Limited ('CRI'), a previously held joint venture which provides products and services to the frequency control industry. Consideration was US\$5.5m and the acquisition is part of the Group's overall manufacturing strategy, providing a low cost manufacturing platform and in addition, access to the local Indian market in the longer term. Consideration of US\$4,125,000 was paid on 2 May 2018 with US\$1,375,000 payable within 18 months of acquisition date. The fair value of the US\$1,375,000 was estimated based on a discount rate of 5.90%.

**B4 b) Details of the purchase consideration, the provisional fair value of net assets acquired and goodwill are as follows**

| <b>Purchase price consideration</b>                       | <b>\$000s</b> |
|-----------------------------------------------------------|---------------|
| Cash paid                                                 | 5,848         |
| Deferred consideration                                    | 1,789         |
| Less deemed settlement of pre-existing net trade payables | (1,249)       |
| <b>Total purchase price consideration</b>                 | <b>6,388</b>  |

|                                                                                                              | <b>Provisional fair value</b> |
|--------------------------------------------------------------------------------------------------------------|-------------------------------|
| <b>The fair value of the assets and liabilities recognised as a result of the acquisition are as follows</b> | <b>\$000s</b>                 |
| Cash and cash equivalents                                                                                    | 1,500                         |
| Property, plant and equipment                                                                                | 3,750                         |
| Inventories                                                                                                  | 5,869                         |
| Trade and other receivables                                                                                  | 5,002                         |
| Trade and other payables                                                                                     | (4,510)                       |
| Overdraft                                                                                                    | (1,320)                       |
| Employee benefit obligations                                                                                 | (343)                         |
| Net deferred tax assets                                                                                      | 1,379                         |
| Less deemed settlement of pre-existing net trade balances                                                    | (1,249)                       |
| <b>Net identifiable assets acquired</b>                                                                      | <b>10,078</b>                 |

As a result of acquisition, the pre-existing 49% share of equity which was acquired on 25 March 2008 was re-measured to fair value and the currency translation reserve relating to pre-existing 49% share of equity was recycled through the profit and loss component of the Statement of Comprehensive Income.

|                                                              | <b>Unaudited six months ended 30 September 2018</b> |
|--------------------------------------------------------------|-----------------------------------------------------|
| <b>Re-measurement of previously held 49% equity interest</b> | <b>\$000s</b>                                       |
| Carrying value of equity interest prior to acquisition       | 2,994                                               |
| Gain on re-measurement                                       | 1,944                                               |
| <b>Re-measured previously held equity interest</b>           | <b>4,938</b>                                        |

|                                                                            |             |
|----------------------------------------------------------------------------|-------------|
| <b>Net loss in business combination on previously held equity interest</b> |             |
| Gain on re-measurement of previously held equity interest                  | 1,944       |
| Loss on reclassification of currency translation reserve                   | (2,013)     |
| <b>Net loss in business combination on previously held equity interest</b> | <b>(69)</b> |

|                                                        |               |
|--------------------------------------------------------|---------------|
| <b>Goodwill on acquisition</b>                         | <b>\$000s</b> |
| Net assets acquired                                    | 10,078        |
| Less fair value of previously held 49% equity interest | (4,938)       |
| Goodwill on acquisition                                | 1,248         |
| <b>Total purchase consideration</b>                    | <b>6,388</b>  |

The goodwill is attributable to synergies expected to arise. None of the goodwill is expected to be deductible for tax purposes.

Deferred tax asset of \$530,000 has been recognised in relation to the fair value adjustments.

The acquisition accounting has been determined on a provisional basis. If new information obtained within one year of the date of acquisition about facts and circumstances that existed at the date of acquisition identifies adjustments to the above amounts, or any additional provisions that existed at the date of acquisition, then the accounting for the acquisition will be revised.

## Acquisition related costs

Acquisition related costs of \$205,000 are included in administrative expenses in the profit and loss component of the Statement of Comprehensive Income.

## Revenue and profit contribution

The acquired business contributed revenues of \$1,980,000 and net profit of \$780,000 to the Group for the period from 2 May 2018 to 30 September 2018. If the acquisition had occurred on 1 April 2018, consolidated revenue and consolidated profit after tax for the half-year ended 30 September 2018 would have been \$2,130,000 and \$660,000, respectively. For April 2018, the Group recorded \$76,000 equity accounted profit for the owned 49% equity interest.

## B5. Interests in associates and joint venture

### B5 a) Accounting policy

Associates are entities over which the Group has significant influence but not control, generally accompanying a shareholding of between 20% and 50% of the voting rights. Investments in associates are accounted for using the equity method of accounting and are initially recognised at cost.

Joint arrangements are classified as either joint operations or joint ventures. The classification depends on the contractual rights and obligations of each investor, rather than the legal structure of the joint arrangement. The Group's joint venture is accounted for using the equity method.

Under the equity method of accounting, the investments are initially recognised at cost and adjusted thereafter to recognise the Group's share of the post-acquisition profits or losses of the investee in profit or loss, and the Group's share of movements in other comprehensive income of the investee in other comprehensive income. Dividends received or receivable from associates and joint ventures are recognised as a reduction in the carrying amount of the investment. When the Group's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the other entity. Unrealised gains on transactions between the Group and its associates and joint ventures are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

### B5 b) Breakdown of associates and joint venture

Set out below are the associates and joint venture of the Group. The entities listed below have share capital consisting solely of ordinary shares, which are held directly by the Group. The country of incorporation or registration is also their principal place of business, and the proportion of ownership interest is the same as the proportion of voting rights held.

| Name of entity                                                                      | Nature of relationship | Country of incorporation | % of ownership interest    |                            |                    |
|-------------------------------------------------------------------------------------|------------------------|--------------------------|----------------------------|----------------------------|--------------------|
|                                                                                     |                        |                          | Unaudited six months ended | Unaudited six months ended | Audited year ended |
|                                                                                     |                        |                          | 30 September 2018          | 30 September 2017          | 31 March 2018      |
| Chengdu Timemaker Crystal Technology Co. Ltd <sup>1</sup>                           | Associate              | China                    | 40%                        | 40%                        | 40%                |
| Shenzhen Taixiang Wafer Co. Ltd <sup>1</sup>                                        | Associate              | China                    | 40%                        | 40%                        | 40%                |
| Thinextra Pty Limited (ceased being an associate June 2018) <sup>3</sup>            | Associate              | Australia                | -                          | 33%                        | 21.4%              |
| Centum Rakon India Private Ltd (ceased being a joint venture May 2018) <sup>2</sup> | Joint venture          | India                    | -                          | 49%                        | 49%                |

|                                                                               | Net investment |               |               | Equity accounted profits/(losses) |               |                |
|-------------------------------------------------------------------------------|----------------|---------------|---------------|-----------------------------------|---------------|----------------|
|                                                                               | Unaudited six  | Unaudited six | Audited year  | Unaudited six                     | Unaudited six | Audited year   |
|                                                                               | months ended   | months ended  | ended         | months ended                      | months ended  | ended          |
|                                                                               | 30 September   | 30 September  | 31 March      | 30 September                      | 30 September  | 31 March       |
|                                                                               | 2018           | 2017          | 2018          | 2018                              | 2017          | 2018           |
|                                                                               | \$000s         | \$000s        | \$000s        | \$000s                            | \$000s        | \$000s         |
| Chengdu Timemaker Crystal Technology Co. Limited <sup>1</sup>                 | 9,531          | 8,383         | 8,925         |                                   |               |                |
| Shenzhen Taixiang Wafer Co. Limited <sup>1</sup>                              | 423            | 416           | 425           |                                   |               |                |
| Total Timemaker Group                                                         | 9,954          | 8,799         | 9,350         | 781                               | 769           | 908            |
| Thinextra Pty Limited <sup>3</sup>                                            | -              | 2,803         | 5,290         | (287)                             | (1,271)       | (2,273)        |
| <b>Total carrying amount of associates</b>                                    | <b>9,954</b>   | <b>11,602</b> | <b>14,640</b> | <b>494</b>                        | <b>(502)</b>  | <b>(1,365)</b> |
| Centum Rakon India Private Limited <sup>2</sup>                               | -              | 3,451         | 2,876         | 76                                | (41)          | (550)          |
| <b>Total carrying amount of equity accounted associates and joint venture</b> | <b>9,954</b>   | <b>15,053</b> | <b>17,516</b> | <b>570</b>                        | <b>(543)</b>  | <b>(1,915)</b> |

<sup>1</sup> The Group has a 40% interest in two related companies: Chengdu Timemaker Crystal Technology Co. Limited and Shenzhen Taixiang Wafer Co. Limited, which provide products and services to the frequency control products industry. In June 2017, Chengdu Shen-Timemaker Crystal Technology Co. Limited, a company in the Timemaker Group, was merged with Chengdu Timemaker Crystal Technology Co. Limited.

<sup>2</sup> On 2 May 2018, the Group assumed full ownership of Centum Rakon India Private Limited ('CRI') by acquiring the remaining 51% interest of shares, refer note B4. Prior to the acquisition, CRI, was a joint venture.

<sup>3</sup> Due to loss of significant influence, on 1 June 2018, the Group has reclassified the investment in Thinextra Pty Limited ('Thinextra'), as a financial asset at fair value through other comprehensive income, refer note B5 c).

#### B5 c) Investment in Thinextra

Thinextra Pty Limited ('Thinextra') is an 'Internet of Things' ('IoT') business that started in 2016. Thinextra's focus is on establishing an IoT network in Australia, New Zealand and Hong Kong and providing products, services and solutions enabling connectivity of devices to the network. Thinextra's business model is based on subscription for access to the network, platform solutions and the sale of IoT products. Further information is available at [www.thinextra.com](http://www.thinextra.com).

The Group commenced equity accounting its investment in Thinextra from December 2015 and ceased this treatment on 31 May 2018. On 1 June 2018, Rakon irrevocably waived its right to appoint a director to Thinextra's board and concurrently Rakon's appointed director resigned. Accordingly, it was concluded that Rakon lost significant influence in Thinextra on 1 June 2018 and therefore ceased equity accounting the investment. On this day, the investment was measured at fair value in accordance with NZ IAS 28 Investments in Associates and Joint Ventures. The fair value was determined by an independent valuation report that provided a price range per share. The lowest price in the range was used to measure the investment to fair value which resulted in a gain of \$7,172,000 being recognised in the profit and loss component of the Statement of Comprehensive Income. The fair value of Rakon's 21.4% of equity holding as at 1 June 2018 is \$12,176,000. The Directors have determined that the fair value has not materially changed between 1 June 2018 and 30 September 2018.

To provide an indication about the reliability of the inputs used in determining fair value, the Group classified the fair valuation of Thinextra investment as a level 3 investment. This is the prescribed method of grouping under the accounting standards which states that the instruments are classified as level 3 only if one or more of the significant inputs for the valuation is not based on observable market data. The valuation of Thinextra was based on an independent valuation report which included the following key judgement and assumptions:

- In October 2017 Thinextra undertook a significant capital raising where demand exceeded supply
- In November 2017 Rakon sold 199,763 shares for A\$3.0m to applicants who missed out on the October 2017 capital raising
- The outlook for Thinextra between October 2017 and June 2018 has not materially changed
- A new capital raising is expected to take place in late 2018.

Further, effective 1 June 2018, the Group elected to present subsequent changes in fair value of its investment in Thinextra in other comprehensive income, refer B8 a) for accounting policy, NZ IFRS 9 Financial Instruments.

A 10% strengthening of the fair value of investment will result in an increase in other comprehensive income component of the Statement of Comprehensive Income by \$1,217,600. A 10% weakening will have an equal but opposite effect.

#### B6. Contingencies

It is not anticipated that any material liabilities will arise from the contingent liabilities.

#### B7. Events after reporting date

There have been no other subsequent events after 30 September 2018.

## B8. Basis of preparation

The Company is registered under the Companies Act 1993 and is a Financial Markets Conduct reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The interim financial statements of the Group have been prepared in accordance with the requirements of Part 7 of the Financial Markets Conduct Act 2013 and the NZX (Main Board) Listing Rules.

These consolidated interim financial statements for the half-year reporting period ended 30 September 2018 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with New Zealand equivalents to International Financial Reporting Standards (NZ IFRS), other New Zealand accounting standards and authoritative notices that are applicable to entities that apply NZ IFRS, in particular IAS 34 Interim Financial Reporting. The consolidated financial statements also comply with International Financial Reporting Standards (IFRS). The Group is a profit-oriented entity for the purposes of complying with NZ GAAP. These financial statements comprise Rakon and its subsidiaries.

The financial statements have been prepared on a historical cost basis, except for the following:

- available-for-sale financial assets, financial assets and liabilities (including derivative instruments) – measured at fair value, and
- assets held for sale – measured at fair value less cost of disposal.

The preparation of financial statements in accordance with NZ IFRS requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Actual results may differ from these estimates. This interim financial report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report should be read in conjunction with the annual report for the year ended 31 March 2018 and any public announcements made by the Company during the interim reporting period. The accounting policies applied are consistent with those of the annual report for the year ended 31 March 2018.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, except for the adoption of new and amended standards as set out below.

### B8 a) New and amended standards adopted by the Group

A number of new or amended standards became applicable for the current reporting period and the Group had to change its accounting policies:

- NZ IFRS 9 Financial Instruments, and
- NZ IFRS 15 Revenue from Contracts with Customers.

The Group has performed the assessment and concluded that there is no material adjustment from adoption of these standards and no retrospective adjustments are required in the consolidated interim financial statements.

#### NZ IFRS 9 Financial Instruments

##### *Classification*

From 1 January 2018, the Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value (either through other comprehensive income (OCI), or through profit and loss), and
- those to be measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income (FVOCI).

##### *Measurement*

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at fair value through profit or loss (FVPL), transaction costs that are directly attributable to the acquisition of the financial asset.

##### *Equity instruments*

The Group subsequently measures all equity investments at fair value. Where the Group's management has elected to present fair value gains and losses on equity investments in OCI, there is no subsequent reclassification of fair value gains and losses to the profit and loss component of the Statement of Comprehensive Income. Dividends from such investments continue to be recognised as other income in the profit and loss component of the Statement of Comprehensive Income when the Group's right to receive payments are established. Changes in the fair value of financial assets at FVPL are recognised in other gains/(losses) in the profit and loss component of the Statement of Comprehensive Income. Impairment losses (and reversal of impairment losses) on equity investments measured at FVOCI are not reported separately from other changes in fair value.

##### *Derivatives and hedging*

The effective portion of changes in the fair value of derivatives that are designated and qualify as cash flow hedges is recognised in the cash flow hedge reserve within equity. The gain or loss relating to the ineffective portion is recognised immediately in profit or loss, within other income (expenses). When option contracts are used to hedge forecast transactions, the Group designates only the intrinsic value of the options as the hedging instrument. Until 31 March 2018, the Group classified foreign currency options as held-for-trading derivatives and accounted for them at FVPL. Gains or losses relating to the effective portion of the change in intrinsic value of the options are recognised in the cash flow hedge reserve within equity. The changes in the time value of the options that relate to the hedged item ('aligned time value')

are recognised within OCI in the costs of hedging reserve within equity. When forward contracts are used to hedge forecast transactions, the Group generally designates only the change in fair value of the forward contract related to the spot component as the hedging instrument. Gains or losses relating to the effective portion of the change in the spot component of the forward contracts are recognised in the cash flow hedge reserve within equity. The change in the forward element of the contract that relates to the hedged item ('aligned forward element') is recognised within OCI in the costs of hedging reserve within equity. In some cases, the entity may designate the full change in fair value of the forward contract (including forward points) as the hedging instrument. In such cases, the gains or losses relating to the effective portion of the change in fair value of the entire forward contract are recognised in the cash flow hedge reserve within equity.

Amounts accumulated in equity are reclassified in the periods when the hedged item affects profit or loss, as follows:

Where the hedged item subsequently results in the recognition of a non-financial asset (such as inventory), both the deferred hedging gains and losses and the deferred time value of the option contracts or deferred forward points, if any, are included within the initial cost of the asset. The deferred amounts are ultimately recognised in profit or loss as the hedged item affects profit or loss (for example through cost of sales).

The gain or loss relating to the effective portion of the interest rate swaps hedging variable rate borrowings is recognised in profit or loss within finance cost at the same time as the interest expense on the hedged borrowings.

When a hedging instrument expires, or is sold or terminated, or when a hedge no longer meets the criteria for hedge accounting, any cumulative deferred gain or loss and deferred costs of hedging in equity at that time remains in equity until the forecast transaction occurs, resulting in the recognition of a non-financial asset such as inventory. When the forecast transaction is no longer expected to occur, the cumulative gain or loss and deferred costs of hedging that were reported in equity are immediately reclassified to profit or loss.

## **B8 b) Impact of standards issued but not yet applied**

### **NZ IFRS 16 Leases**

NZ IFRS 16 was issued in January 2016. It will result in almost all leases being recognised on the balance sheet, as the distinction between operating and finance leases is removed. Under the new standard, an asset (the right to use the leased item) and a financial liability to pay rentals are recognised. The only exceptions are short-term and low-value leases.

The accounting for lessors will not significantly change.

The standard will affect primarily the accounting for the Group's operating leases. The full impact of this standard has not yet been determined. However, this will result in additional assets and liabilities when the current operating leases are recognised on to the balance sheet. Interest and depreciation expenses will replace the current operating lease expenses in the profit and loss component of the Statement of Comprehensive Income.

The standard is mandatory for first interim periods within annual reporting periods beginning on or after 1 January 2019. The Group does not intend to adopt the standard before its effective date.

# Directory

---

## Registered Office

Rakon Limited  
8 Sylvia Park Road  
Mt Wellington  
Auckland 1060  
Telephone: +64 9 573 5554  
Facsimile: +64 9 573 5559  
Website: [www.rakon.com](http://www.rakon.com)

## Mailing Address

Rakon Limited  
Private Bag 99943  
Newmarket  
Auckland 1149

## Directors

Bruce Irvine  
Bryan Mogridge (*ceased 7 August 2018*)  
Keith Oliver  
Brent Robinson  
Roger Yao  
Yin Tang Tseng  
Lorraine Witten  
Keith Watson (*appointed 21 September 2018*)

## Principal Lawyers

Bell Gully  
PO Box 4199  
Shortland Street  
Auckland 1140

## Auditors

PricewaterhouseCoopers  
Private Bag 92162  
Auckland 1142

## Share Registrar

Computershare Investor Services Limited  
Private Bag 92119  
Victoria Street West  
Auckland 1142

### *Managing Your Shareholding Online:*

To change your address, update your payment instructions  
and to view your investment portfolio including transactions, please visit:  
[www.investorcentre.com/nz](http://www.investorcentre.com/nz)

### *General enquiries can be directed to:*

[enquiry@computershare.co.nz](mailto:enquiry@computershare.co.nz)  
Telephone: +64 9 488 8777  
Facsimile: +64 9 488 8787

## Bankers

ASB Bank  
PO Box 35  
Shortland Street  
Auckland 1140



**rakon**

[www.rakon.com](http://www.rakon.com)